Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 2Phase 2/3 2Phase 1/2 2Phase 1 1

Status

Unknown 25Recruiting 5Not yet recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Esophageal Neoplasms 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × camrelizumab × Clear all
NCT05176002 2025-11-19

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Fujian Medical University Union Hospital

Phase 1/2 Active not recruiting
25 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Fudan University

Phase 1/2 Active not recruiting
25 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡